With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more
NVO is expected to report earnings to rise 39.36% to 96 cents per share on February 04
Q4'25
Est.
$0.96
Q3'25
Missed
by $0.09
Q2'25
Est.
$0.93
Q1'25
Beat
by $5.64
Q4'24
Beat
by $5.46
The last earnings report on November 05 showed earnings per share of 69 cents, missing the estimate of 78 cents. With 7.23M shares outstanding, the current market capitalization sits at 216.23B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NVO showed earnings on November 05, 2025. You can read more about the earnings report here.